Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Symptom improvement
研究概览
简要总结
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.
详细描述
COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .
Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •COVID-19 Patients with keratoconjunctivitis
排除标准
- •associated ocular pathology or disease
- •other causes of keratoconjunctivitis for example allergic or herpetic
研究组 & 干预措施
COVID-19 keratoconjunctivitis
cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
干预措施: topical steroids and cyclosporin-A (Drug)
结局指标
主要结局
Symptom improvement
时间窗: 10-15 days
eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling
Signs improvement
时间窗: 10-15 days
conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva
次要结局
未报告次要终点
研究者
Ameera Gamal Abdelhameed
Lecturer of Ophthalmology
Mansoura University